Iq Eq Management

12 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 28, 2026
The maintenance fee for Stable oral solutions for combined API (US 10,300,015) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
1 fee due Feb 20, 2027
The maintenance fee for Early treatment of CMT disease (US 10,383,870) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
1 fee due Sep 10, 2027
The maintenance fee for Compositions for treating CMT and related disorders (US 10,583,135) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,393,241	Compositions for treating CMT and related disorders In force Ends no later than May 28, 2030 · From the USPTO record	In force	Ends no later than May 28, 2030	From the USPTO record
US 9,427,436	Compositions for treating CMT and related disorders In force Ends no later than May 28, 2030 · From the USPTO record	In force	Ends no later than May 28, 2030	From the USPTO record
US 9,566,275	Compositions for treating CMT and related disorders In force Ends no later than May 28, 2030 · From the USPTO record	In force	Ends no later than May 28, 2030	From the USPTO record
US 10,583,135	Compositions for treating CMT and related disorders In force Term ends Sep 16, 2030 · From the USPTO record	In force	Term ends Sep 16, 2030	From the USPTO record
US 8,992,891	Therapeutic approaches for treating CMT and related disorders In force Term ends Jul 26, 2031 · From the USPTO record	In force	Term ends Jul 26, 2031	From the USPTO record
US 10,273,462	Virus-based vector compositions useful for transducing eukaryotic cells In force Term ends Sep 13, 2032 · From the USPTO record	In force	Term ends Sep 13, 2032	From the USPTO record
US 9,567,634	Method for detecting or measuring the impact of a viral vector composition on eukaryotic cells and biomarkers used thereof In force Term ends Jul 26, 2033 · From the USPTO record	In force	Term ends Jul 26, 2033	From the USPTO record
US 10,300,015	Stable oral solutions for combined API In force Term ends Jun 5, 2034 · From the USPTO record	In force	Term ends Jun 5, 2034	From the USPTO record
US 10,870,865	Particle for the Encapsidation of a Genome Engineering System In force Term ends May 18, 2037 · High confidence	In force	Term ends May 18, 2037	High confidence
US 10,383,870	Early treatment of CMT disease In force Term ends Jun 9, 2037 · From the USPTO record	In force	Term ends Jun 9, 2037	From the USPTO record

10 of 12 patents shown.

Pro members see all 12.

Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro